Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a decrease in revenue and increased expenses, leading to a higher net loss. The Q&A section reveals uncertainties in pricing strategies and potential market risks. Although there are positive regulatory milestones and strategic initiatives, the financial challenges and lack of clear guidance on pricing strategies suggest a negative sentiment. Additionally, the public offering and the need for further funding introduce concerns about financial health. Overall, these factors contribute to a negative outlook for the stock price over the next two weeks.
Key Financial Performance
Revenues for the 6 months ended June 30, 2025 $0.7 million, a decrease of $0.3 million or 31% year-over-year. The decline was driven primarily by decreased participant demand for the Bahamas registry trial and reduced demand for contract manufacturing services from third-party clients.
Clinical trial revenue for the 6 months ended June 30, 2025 $0.6 million, a decrease of $0.2 million or 31% year-over-year. This decline was primarily a result of decreased participant demand.
Contract manufacturing revenue for the 6 months ended June 30, 2025 $0.1 million, a decrease of approximately $0.1 million or 35% year-over-year. This was due to reduced demand for contract manufacturing services.
General and administrative expenses for the 6 months ended June 30, 2025 $5.5 million, an increase of approximately $1.2 million or 28% year-over-year. The increase was primarily related to an increase in personnel and related costs, including equity-based compensation.
Research and development expenses for the 6 months ended June 30, 2025 $5.5 million, an increase of approximately $1.6 million or 39% year-over-year. The increase was primarily due to a $1.3 million rise in personnel and related costs, including equity-based compensation, and a $0.2 million increase in amortization expense related to patent costs. This was partially offset by $0.3 million in lower clinical trial expenses due to the discontinuation of activities related to the aging-related frailty clinical trial in Japan.
Net loss for the 6 months ended June 30, 2025 $10 million, an increase from $7.5 million year-over-year. This was due to the reasons outlined above, including increased general and administrative and research and development expenses.
Cash and cash equivalents as of June 30, 2025 $10.3 million. Additionally, the company raised approximately $5 million in gross proceeds through a public offering in August, with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Laromestrocel: Positive results across 5 clinical trials in 3 indications: Alzheimer's disease, aging-related frailty, and HLHS. Pivotal Phase 2b study for HLHS completed enrollment, with potential BLA submission in late 2026. New technology licensed from the University of Miami for cardiac applications.
Market Opportunities: Targeting U.S. market opportunities of $5+ billion for Alzheimer's, $4+ billion for aging-related frailty, and up to $1 billion for HLHS.
Manufacturing Strategy: Transitioning to third-party CDMO for commercial manufacturing while maintaining internal capabilities for early-phase programs. Advancing BLA readiness with technology transfer and process validation.
Financial Position: Raised $5 million in public offering with potential for $12.5 million more. Cash reserves expected to fund operations into Q1 2026.
Pipeline Expansion: Added pediatric dilated cardiomyopathy program and licensed new stem cell technology for cardiac applications. Focused on rare diseases with unmet needs.
Partnerships: Seeking strategic collaborations for Alzheimer's program and exploring non-dilutive funding options.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Pathway Challenges: The company acknowledges the demanding and challenging nature of interactions with the FDA, which could potentially delay or complicate the approval process for laromestrocel in HLHS, Alzheimer's disease, and pediatric dilated cardiomyopathy.
Financial Constraints: The company faces significant financial challenges, with a net loss of $10 million for the first half of 2025 and limited cash reserves projected to last only until Q1 2026. Additional financing is required to sustain operations and fund critical development programs.
Manufacturing and CMC Readiness: The company is transitioning to third-party commercial manufacturing for laromestrocel, which involves complex technology transfer and validation processes. Any delays or issues in this transition could impact the timeline for BLA submission and commercialization.
Market Demand Uncertainty: There is a noted decrease in participant demand for the Bahamas registry trial and contract manufacturing services, which could indicate broader market challenges or reduced interest in the company's offerings.
Pipeline Expansion Risks: The expansion into pediatric dilated cardiomyopathy and new stem cell technologies involves significant uncertainties, including the need for additional financing and the inherent risks of developing new therapies.
Operational and Strategic Execution Risks: The company acknowledges the need for efficient capital allocation and operational execution to meet its ambitious milestones, including the BLA submission for HLHS and potential partnerships for Alzheimer's disease.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
HLHS Program: The company anticipates top-line results from the ELPIS II Phase 2b trial in Q3 2026. If results are positive, a rolling BLA submission with the FDA is expected in late 2026. The program is focused on addressing unmet medical needs in pediatric heart conditions, with a potential market opportunity of up to $1 billion.
Alzheimer's Disease Program: The company plans to pursue strategic collaborations and partnerships to advance the laromestrocel therapy. A single pivotal Phase 2/3 clinical trial is planned, which, if successful, would support a BLA submission.
Pediatric Dilated Cardiomyopathy: The company plans to initiate a Phase 2 pivotal registration clinical trial in the first half of 2026, subject to obtaining necessary financing. This program targets a significant unmet need in pediatric heart conditions.
Manufacturing Readiness: The company is advancing its BLA readiness by focusing on technology transfer, process, and analytical method validation planning. Commercial manufacturing will be pursued through a third-party CDMO to support future demand.
Financial Outlook: The company raised $5 million in gross proceeds in August 2025, with potential additional proceeds of $12.5 million from warrant exercises. Current cash reserves are expected to fund operations into Q1 2026. Additional financing will be sought to support increased operating expenses and capital expenditures related to BLA-enabling activities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you confirm whether the target patient populations and addressable markets in HLHS and pediatric dilated cardiomyopathy are similarly sized?
A:The markets are similar but not identical. HLHS has a prevalence of about 1,000 patients in the U.S., while pediatric dilated cardiomyopathy has a prevalence of 2,000-3,000 patients. The incidence of pediatric dilated cardiomyopathy is lower (about 600 patients) compared to HLHS. Pricing strategies are not finalized but are expected to be comparable, with differences in administration methods and usage frequency.
Q:Would a favorable approval decision in HLHS have implications for the regulatory outlook in PBC?
A:Positive data from HLHS would support the regulatory review process for PBC. However, the FDA would still require study results specific to PBC to evaluate endpoints. The Phase 2 study for PBC has been agreed upon with the FDA as sufficient for approval upon positive results.
Q:How does the cost of the proposed Phase 2 study in pediatric dilated cardiomyopathy compare to the HLHS ELPIS II trial?
A:The total cost of the Phase 2 study is estimated at $15-20 million, spanning 4-5 years, with an annual cost of about $3 million. This is considered manageable, and the company is seeking non-dilutive funding to support the trial.
Q:Do you still retain benefits like rolling submission and frequent FDA interactions if the PRV program sunsets in 2026?
A:Yes, the company retains benefits like rolling submission through the rare pediatric disease designation and Fast Track designation for HLHS. They plan to start rolling submissions immediately after data readout next year.
Q:Are there any leadership changes at the FDA that could impact the Phase 2b study being registration-enabling?
A:The company has had multiple interactions with the FDA under the new administration, including face-to-face meetings. The FDA has been collaborative and supportive, and the company plans further interactions to validate all aspects of the program.
Q:Is there a 6-year survival data available for HLHS participants?
A:No, the study was set up to track 5-year survival after the Glenn procedure, and no 6-year data is available.
Q:What are the pros and cons of self-manufacturing versus using a CDMO for laromestrocel?
A:Using a CDMO avoids potential delays in BLA submission, is more cost-effective than renovating existing facilities, and leverages the CDMO's proven regulatory track record, reducing risks.
Q:What gave the FDA confidence to allow a pivotal Phase 2 study in pediatric dilated cardiomyopathy?
A:The study's rigorous endpoints, meaningful clinical features, and robust safety data from over 550 patients contributed to the FDA's confidence. Additionally, prior adult studies with favorable responses and transparent communication with the FDA played a role.
Q:What sort of improvement in survival or time to transplant would be considered clinically meaningful in DCM?
A:Any measurable reduction in all-cause mortality or heart failure hospitalization is considered meaningful. The study aims to prolong transplant-free survival, improve symptoms, and potentially achieve remission in some cases.
Q:How is the iPSC platform differentiated from other cell transplant therapies?
A:The iPSC platform identifies and eliminates cells causing electrical instability, reducing the risk of malignant ventricular arrhythmias. This patented technology focuses on repopulating heart muscle cells without introducing electrical instability.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding finalized pricing strategies for HLHS and pediatric dilated cardiomyopathy, stating only that they should be comparable without offering specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMC manufacturing
ELPIS II
Founder Chief
HLHS BLA
IND application
LLC Research
Longeveron
Nataliya
Research Division
Results Update
Unidentified
VP
Wael
age
approach
arrhythmia
cardiomyopathy
cause
cell heart
cell research
cell technology
child DCM
child treatment
commitment
effect
exercise
expansion
heart failure
infant
laromestrocel
month period
muscle cell
patent
pluripotent
receptor
transplant
year
LGVN Transcript
Longeveron Inc. (LGVN) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary shows a positive financial performance with a 15% revenue increase and reduced net loss, but lacks strategic updates or guidance. The absence of strategic discussions or clear future outlooks, combined with no significant shareholder return announcements, suggests a neutral market reaction. The company's small market cap could lead to more volatility, but the lack of new information tempers any strong positive or negative sentiment.
Longeveron Inc. (LGVN) Q4 2025 Earnings Call Transcript
Unknown3-17
The earnings call summary indicates declining revenue, increased expenses, and a significant net loss, all of which are negative financial indicators. The Q&A reveals management's uncertainty in monetizing PRVs and dependence on strategic partnerships, which are risky. Despite some positive developments in manufacturing and potential partnerships, the overall financial health is concerning. The lack of clear guidance and reliance on future approvals adds to the negative sentiment. Given these factors and the absence of a market cap to gauge volatility, a strong negative stock price movement is likely.
Longeveron Inc. (LGVN) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call reveals several concerns: increasing expenses and net loss, a postponed BLA submission, and vague management responses in the Q&A. Despite potential partnerships and strategic plans, the financial health and uncertainties around funding and timelines overshadow positive aspects. The increase in research and development expenses and the net loss, coupled with the postponed BLA submission, contribute to a negative outlook. The lack of clear guidance and specific plans to expedite regulatory processes further dampens sentiment, leading to a prediction of a negative stock price movement.
Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call summary indicates a decrease in revenue and increased expenses, leading to a higher net loss. The Q&A section reveals uncertainties in pricing strategies and potential market risks. Although there are positive regulatory milestones and strategic initiatives, the financial challenges and lack of clear guidance on pricing strategies suggest a negative sentiment. Additionally, the public offering and the need for further funding introduce concerns about financial health. Overall, these factors contribute to a negative outlook for the stock price over the next two weeks.
LGVN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
